Early trials of adoptively transferred anti-BCR-ABL T-cells have proven safe with some evidence of disease response, however, the success of tyrosine kinase inhibitors in CML has largely overshadowed the development of ACT for this disease[56, 57]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.